Hydroxyapatite toothpaste,
does it really help with Enamel remineralization without fluoride and caries prevention comparable to fluoride toothpaste?
research showsC. Hydroxyapatite toothpaste has a human signal for enamel remineralization and caries prevention without fluoride. Six-, 12-, and 18-month noninferiority trials in children and adults mean the evidence is not D. The noninferiority margin was as wide as 20%, however, and trials, products, and investigators were concentrated around one manufacturer, leaving weak independent replication. It cannot be equated with verdict 701 on fluoride toothpaste, rated A92 from dozens of randomized trials and Cochrane evidence. The manufacturer-positive ceiling gives C with 54 points.
ads claimMarketing expands a surface-repair remineralization mechanism into claims of complete equivalence or superiority to fluoride. Current evidence shows non-inferiority of particular HAP formulations in a limited set of trials, not equivalence of every product or superiority to fluoride.
Useful facts when choosing a product
- Hydroxyapatite is a calcium phosphate similar to the main mineral in tooth enamel, and toothpaste products vary in particle size, form, and concentration.
- Direct anticaries trials largely tested specific microcrystalline HAP toothpastes used two or three times daily, so the findings do not automatically apply to products with undisclosed concentrations or different formulations.
- Brushing quality, frequency of sugar intake, interdental cleaning, and regular dental examinations affect caries risk independently of toothpaste ingredients, and high-risk users should discuss fluoride use with a dentist.
- HAP toothpaste meeting defined specifications is generally well tolerated and does not create a dental-fluorosis risk when swallowed. Nano-HAP safety assessments are conditional on particle shape, size, and concentration, so toothpaste still should not be deliberately swallowed.
What the research actually shows
Schlagenhauf 2019 followed 150 high-risk orthodontic patients for six months and reported non-inferiority to 1,400-ppm fluoride toothpaste for new ICDAS lesions. Paszynska 2021 followed 207 children for one year; ICDAS progression occurred in 72.7% with HAP and 74.2% with fluoride, and the upper confidence limit of 9.8% remained within the prespecified 20% margin. Paszynska 2023 followed 189 adults by intention to treat for 18 months and found no DMFS increase in 89.3% with HAP and 87.4% with fluoride in the per-protocol analysis. These are direct clinical signals, but a 20% margin and industry ties limit precision.
Why this is classified as C (54)
C. Direct six-, 12-, and 18-month trials provide a noninferiority signal for caries lesions or DMFS, so the evidence is not D. Margins reached 20%, trials, products, and investigators were concentrated around one manufacturer, and independent replication is weak. This is not comparable to the dozens of randomized trials and Cochrane evidence behind the A92 fluoride-toothpaste verdict 701. The manufacturer-positive ceiling gives C with 54 points, with safety and product variation kept separate.
Counterpoint. Fluoride toothpaste remains the benchmark with a much larger independent evidence base. Anyone choosing hydroxyapatite should check whether the concentration and formulation resemble those tested and use dental examinations to monitor new caries.
Rejudgment record. Reassessment (cross-check reflected) — Accepted human anticaries signals from six-, 12-, and 18-month noninferiority trials and therefore excluded D, but applied the manufacturer-positive ceiling of C because the margin reached 20%, trials, products, and investigators were concentrated around one manufacturer, independent replication was weak, and the evidence base was far smaller than the dozens of randomized trials and Cochrane synthesis behind the A92 fluoride-toothpaste verdict 701
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Enamel remineralization and caries prevention | C | Direct noninferiority trials provide a human signal, but wide margins and manufacturer concentration impose a C ceiling. |
| Noninferiority to fluoride toothpaste with a 20% margin and industry concentration | ? | Design and conflict features limit interpretation of noninferiority and do not support a separate efficacy grade. |
| Extension into superiority over fluoride | ? | No adequate direct trial establishes superiority over fluoride toothpaste. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Schlagenhauf U et al. 2019 | Randomized controlled non-inferiority trial | 147 | Supported by Dr. Kurt Wolff GmbH with related conflicts of interest | New enamel lesions of ICDAS 1 or higher over six months | Lesion progression occurred in 56.8% with HAP and 60.9% with fluoride, meeting the prespecified non-inferiority criterion. | Direct clinical endpoint with industry involvement |
| Paszynska E et al. 2021 | Double-blind randomized non-inferiority trial | 177 | Supported by Dr. Kurt Wolff GmbH | Increase of ICDAS 1 or higher in primary teeth over one year | Progression was 72.7% with HAP and 74.2% with fluoride; the one-sided 95% upper limit was 9.8%, within the 20% margin. | Direct pediatric evidence with a wide margin |
| Paszynska E et al. 2023 | Eighteen-month double-blind randomized non-inferiority trial | 171 | Three manufacturer employees were coauthors with product-related conflicts | Proportion of participants with no increase in DMFS | In the per-protocol analysis, 89.3% with HAP and 87.4% with fluoride had no DMFS increase, meeting non-inferiority. | Direct longer adult evidence with industry involvement |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-19).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-19 · Corrections: none
Cite this verdict
[Chamgap] Hydroxyapatite toothpaste x enamel remineralization and caries prevention — Evidence Grade C·54. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/general/hydroxyapatite-toothpaste-enamel-remineralization-caries-prevention/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.